Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.

Autor: Duell, J., Abrisqueta, P., Andre, M., Augustin, M., Gaidano, G., Barca, E. G., Jurczak, W., Kalakonda, N., Liberati, A. M., Maddocks, K. J., Menne, T., Nagy, Z., Tournilhac, O., Bakuli, A., Amin, A., Gurbanov, K., Salles, G.

Publikováno v: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p437-439, 3p

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Autor: Shah, J. Shacham, S. Kauffman, M. Daniele, P. Tomaras, D. Tremblay, G. Casasnovas, R.-O. Maerevoet, M. Zijlstra, J. Follows, G. P Vermaat, J.S. Kalakonda, N. Goy, A.H. Choquet, S. Den Neste, E.V. Hill, B.T. Thieblemont, C. Cavallo, F. La Cruz, F.D. Kuruvilla, J. Hamad, N. Bouabdallah, R. Jäger, U. Caimi, P. Gurion, R. Warzocha, K. Bakhshi, S. Sancho, J.M. Schuster, M. Egyed, M. Offner, F. Vasilakopoulos, T.P. Samal, P. Nagy, A. Ku, M. Canales Albendea, M.Á.

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::0e2f811591694d3135f36e92cda83222
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077132

Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial

Autor: Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J.S.P., Casasnovas, O., Hamad, N., Zijlstra, J.M., Bakhshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J.M., Schuster, M., Thieblemont, C., Cruz, F. de la, Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T.P., Warzocha, K., McCarthy, D., Ma, X.W., Corona, K., Saint-Martin, J.R., Chang, H., Landesman, Y., Joshi, A., Wang, H.W., Shah, J., Shacham, S., Kauffman, M., Neste, E. van den, Canales, M.A.

Publikováno v: Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Lancet Haematology, 7(7), E509-E522. ELSEVIER SCI LTD

Background Relapsed or refractory diffuse large B -cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single -agent selinexor, an oral selective inhibitor of nuclear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0b56206d52c8c303f1c0c046e72501ef
https://hdl.handle.net/1887/3185058